首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

2084771

僵直性脊椎炎市場：依藥物類型、給藥途徑、通路及地區分類

Ankylosing Spondylitis Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年06月18日 | 出版商:

Coherent Market Insights | 英文 255 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，僵直性脊椎炎市場規模將達到 72.8 億美元，到 2033 年將達到 114 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 6.51%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	72.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.51%	2033年市場規模預測：	114億美元

由於僵直性脊椎炎盛行率上升、生物製藥的採用率不斷提高、生物相似藥的供應量不斷擴大以及人們對早期診斷和疾病管理的認知不斷提高，預計市場將穩步成長。

僵直性脊椎炎（AS）是一種慢性發炎性自體免疫疾病，主要涉及脊椎和骶髂關節，導致疼痛、僵硬和進行性性活動範圍受限。此疾病還可涉及周邊關節和關節外器官，顯著影響患者的生活品質（QOL）。醫護人員和患者對該疾病認知的提高，以及影像技術和基於生物標記的診斷方法的進步，正有助於早期診斷和改善治療效果。

標靶生物製藥（包括腫瘤壞死因子 (TNF) 抑制劑和白細胞介素-17 (IL-17) 抑制劑）的廣泛應用進一步推動了市場成長，這些藥物徹底改變了治療格局。生物相似藥的核准以及精準醫療的持續研究正在改善患者獲得治療的機會並拓展治療選擇。國際僵直性脊椎炎評估學會 (ASAS)、美國風濕病學會 (ACR) 和歐洲抗風濕病聯盟 (EULAR) 等組織不斷完善疾病管理指南，促進先進療法的應用。

市場動態

僵直性脊椎炎市場的發展受到流行病學、技術和治療因素的共同驅動。

僵直性脊椎炎和中軸型脊椎關節炎在全球的盛行率不斷上升，是推動該成長要素之一。人們對這些疾病的認知不斷提高，加上基於磁振造影（MRI）的診斷工具和HLA-B27基因檢測的普及，提高了診斷率，並使早期治療性介入成為可能。早期診斷有助於預防結構性損傷，改善長期臨床療效，從而推動了對有效治療方法的需求。

另一個主要的成長要素是生物製藥和標靶治療的廣泛應用。雖然TNF抑制劑已成為中度和重度疾病的標準治療方案，但IL-17抑制劑作為新一代生物製藥正在崛起，為那些對TNF抑制劑反應不佳的患者帶來治療益處。生物相似藥在已開發市場和新興市場的快速普及正在降低治療成本，並改善患者的用藥可及性。

人工智慧影像分析、數位生物標記、電子健康記錄、穿戴式監測設備和患者報告結局（PRO）平台等技術創新正在進一步加強疾病監測和個人化醫療。這些進步有助於更好地管理疾病，並提高患者的治療依從性。

然而，該市場面臨許多挑戰，例如生物製藥治療高成本、由於與其他肌肉骨骼疾病症狀重疊而導致診斷延遲，以及中低收入國家獲得先進治療的機會有限。儘管存在這些限制，但對精準醫療、生物標記研究和下一代標靶治療的持續投資預計將在預測期內創造顯著的成長機會。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數分析僵直性脊椎炎市場的主要參與者：公司概況、服務組合、主要發展、財務表現和策略。
本報告提供的見解將使行銷負責人和經營團隊能夠就未來的服務創新、市場擴張和策略合作夥伴關係做出明智的決策。
《僵直性脊椎炎市場報告》的目標對象包括投資者、服務供應商、製藥公司、監管機構和金融分析師等各類相關人員。
相關人員可以從用於評估僵直性脊椎炎市場的系統分析框架和策略矩陣中受益。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Amgen Inc.
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- CELGENE CORPORATION
- Eli Lilly and Company
- Cipla Inc.
- Emcure Pharmaceuticals
- Torrent Pharmaceuticals Ltd.
- UCB SA
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- HENGRUI USA
- Johnson & Johnson Services, Inc.
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI4833

Ankylosing Spondylitis Market is estimated to be valued at USD 7.28 Bn in 2026 and is expected to reach USD 11.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.51% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.28 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.51%	2033 Value Projection:	USD 11.40 Bn

The market is projected to witness steady growth owing to the rising prevalence of ankylosing spondylitis, increasing adoption of biologic therapies, expanding availability of biosimilars, and growing awareness regarding early diagnosis and disease management.

Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disorder that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and progressive loss of mobility. The disease can also affect peripheral joints and extra-articular organs, thereby significantly impacting quality of life. Growing awareness among healthcare professionals and patients, coupled with advancements in imaging technologies and biomarker-based diagnostics, is contributing to earlier diagnosis and improved treatment outcomes.

The market growth is further supported by increasing use of targeted biologic therapies, including tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, which have transformed the treatment landscape. Regulatory approvals of biosimilars and ongoing research in precision medicine are improving treatment accessibility and expanding therapeutic options. Organizations such as the Assessment of SpondyloArthritis International Society (ASAS), the American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR) continue to strengthen disease management guidelines, supporting wider adoption of advanced therapies.

Market Dynamics

The Ankylosing Spondylitis Market is driven by a combination of epidemiological, technological, and therapeutic factors.

One of the primary growth drivers is the increasing prevalence of ankylosing spondylitis and axial spondyloarthritis worldwide. Growing disease awareness and the availability of MRI-based diagnostic tools and HLA-B27 genetic testing are improving diagnosis rates and enabling early treatment intervention. Early diagnosis helps prevent structural damage and enhances long-term clinical outcomes, thereby driving demand for effective therapies.

Another major growth factor is the expanding use of biologics and targeted therapies. TNF inhibitors have become the standard treatment for moderate-to-severe disease, while IL-17 inhibitors have emerged as next-generation biologics offering therapeutic benefits for patients who do not adequately respond to anti-TNF agents. The rapid penetration of biosimilars across developed and emerging markets is lowering treatment costs and improving patient accessibility.

Technological innovations such as AI-assisted imaging analysis, digital biomarkers, electronic health records, wearable monitoring devices, and patient-reported outcome platforms are further enhancing disease monitoring and personalized care. These advancements are supporting better disease management and improving patient adherence to treatment.

However, the market faces challenges including high costs associated with biologic therapies, delayed diagnosis due to symptom overlap with other musculoskeletal disorders, and limited access to advanced treatments in low- and middle-income countries. Despite these restraints, ongoing investments in precision medicine, biomarker research, and next-generation targeted therapies are expected to create significant growth opportunities throughout the forecast period.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Ankylosing Spondylitis Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
The Ankylosing Spondylitis Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Ankylosing Spondylitis Market.

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021-2033)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Disease-modifying anti-rheumatic drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
By Route of Administration (Revenue, USD Bn, 2021-2033)
Oral
Parenteral
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Amgen Inc.
AbbVie Inc.
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
CELGENE CORPORATION
Eli Lilly and Company
Cipla Inc.
Emcure Pharmaceuticals
Torrent Pharmaceuticals Ltd.
UCB S.A.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
HENGRUI USA
Johnson & Johnson Services, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Ankylosing Spondylitis Market, By Drug Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
TNF Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Ankylosing Spondylitis Market, By Route of Administration, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Ankylosing Spondylitis Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Ankylosing Spondylitis Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- CELGENE CORPORATION
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Cipla Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Emcure Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Torrent Pharmaceuticals Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- UCB S.A.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- HENGRUI USA
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Johnson & Johnson Services, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views